Business Wire·Nov 13, 2025, 4:01 PM ET

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics announced financial and operating results for the third quarter ended September 30, 2025.
Topline data from the Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) is anticipated in the first half of 2026.
Results from the healthy volunteer study of next-generation STAT3 inhibitor TTI-109 are also expected in the first half of 2026.
The company reported preliminary data from the Phase 2 REVERT IPF trial in October, concluding the study did not meet its goals while additional analyses are underway.
Research and development expenses for the quarter were $3.6 million, down from $4.8 million in the prior year period, driven by lower HCC trial costs 2025.
General and administrative expenses increased to $2.3 million from $0.9 million, primarily due to higher professional fees, personnel costs, insurance, 2025.
Net loss for the quarter was $5.5 million, roughly flat with the comparable period in 2024, resulting in a net loss per share of $0.59.
Cash, cash equivalents, 2025, and short-term investments as of September 30, 2025, totaled $36.5 million.
The company's cash runway is sufficient to fund operations into the fourth quarter of 2026.
Tvardi is advancing TTI-109, which is designed to convert rapidly to TTI-101 to improve tolerability by reducing exposure of the active drug to the intestinal lining.